

FDA Staff Manual Guides, Volume I – Organizations and Functions

Department of Health and Human Services

Food and Drug Administration

Center for Veterinary Medicine

Office of New Animal Product Evaluation

Division of Companion Animal Drugs

Effective Date: August 23, 2024

1. Division of Companion Animal Drugs (DCGCC).

- A. Manages the evaluation of animal safety and effectiveness under new animal drug applications for wildlife and companion animals; oversees proposed labeling reviews to assure that it clearly indicates the use and limitations of the product and provides other required information; establishes procedures to evaluate the safety and effectiveness of drugs for wildlife and companion animals; and provides such information to investigators and developers.
- B. Verifies the adequacy of information submitted to support proposed use of investigational drugs in wildlife and companion animals.
- C. Manages intramural and extramural research projects to gain further information on drugs for wildlife and companion animals.
- D. Manages the development and implementation of regulations, guidance, and policies pertaining to drugs intended for use in wildlife and companion animals.
- E. Provides technical support and expert testimony in legal proceedings relative to the approval of new animal drugs for wildlife and companion animals.
- F. Develops short and long-range work plans and staffing need proposals for the Division.

2. Companion Animal Branch 1 (DCGCC1).

- A. Evaluates, for animal safety and effectiveness, new animal drug applications for wildlife and companion animals; evaluates proposed labeling to assure that it clearly indicates the use and limitations of the product and provides

other required information; recommends procedures to establish the safety and effectiveness of drugs for wildlife and companion animals; and provides such information to investigators and developers.

- B. Determines the adequacy of information submitted to support proposed use of investigational drugs in wildlife and companion animals.
- C. Recommends, and may participate in, intramural and extramural research projects to gain further information on drugs for wildlife and companion animals.
- D. Participates in the development and implementation of regulations, guidance, and policies pertaining to drugs intended for use in wildlife and companion animals.
- E. Provides technical support and expert testimony in legal proceedings relative to the approval of new animal drugs for wildlife and companion animals.

3. Companion Animal Branch 2 (DCGCC2).

- A. Evaluates, for animal safety and effectiveness, new animal drug applications for wildlife and companion animals; evaluates proposed labeling to assure that it clearly indicates the use and limitations of the product and provides other required information; recommends procedures to establish the safety and effectiveness of drugs for wildlife and companion animals; and provides such information to investigators and developers.
- B. Determines the adequacy of information submitted to support proposed use of investigational drugs in wildlife and companion animals.
- C. Recommends, and may participate in, intramural and extramural research projects to gain further information on drugs for wildlife and companion animals.
- D. Participates in the development and implementation of regulations, guidance, and policies pertaining to drugs intended for use in wildlife and companion animals.
- E. Provides technical support and expert testimony in legal proceedings relative to the approval of new animal drugs for wildlife and companion animals.

4. Companion Animal Branch 3 (DCGCC3).

- A. Evaluates, for animal safety and effectiveness, new animal drug applications for wildlife and companion animals; evaluates proposed labeling to assure that it clearly indicates the use and limitations of the product and provides other required information; recommends procedures to establish the safety


and effectiveness of drugs for wildlife and companion animals; and provides such information to investigators and developers.

- B. Determines the adequacy of information submitted to support proposed use of investigational drugs in wildlife and companion animals.
- C. Recommends, and may participate in, intramural and extramural research projects to gain further information on drugs for wildlife and companion animals.
- D. Participates in the development and implementation of regulations, guidance, and policies pertaining to drugs intended for use in wildlife and companion animals.
- E. Provides technical support and expert testimony in legal proceedings relative to the approval of new animal drugs for wildlife and companion animals.

5. Authority and Effective Date.

The functional statements for the Division of Companion Animal Drugs were approved by the Secretary of Health and Human Services on July 22, 2024, and effective on August 23, 2024.

**Department of Health and Human Services
Food and Drug Administration
Center for Veterinary Medicine
Office of New Animal Product Evaluation
Division of Companion Animal Drugs**



Staff Manual Guide 1243.12

Organizations and Functions

Effective Date: August 23, 2024

The following is the Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Product Evaluation, Division of Companion Animal Drugs organization structure depicting all the organizational structures reporting to the Director:

Division of Companion Animal Drugs (DCGCC)

Companion Animal Branch 1 (DCGCC1)

Companion Animal Branch 2 (DCGCC2)

Companion Animal Branch 3 (DCGCC3)